
News|Articles|December 1, 2012
Escitalopram reduces the risk of depression in patients with HCV treated with interferon alpha
Pre-emptive therapy with the selective serotonin reuptake inhibitor escitalopram in patients initiating interferon therapy for hepatitis C virus (HCV) without psychiatric risk factors reduced the risk of depression, according to a recent study published in the Annals of Internal Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
COVID-19 vaccines could help tumors respond better to immune checkpoint inhibitors
2
Keytruda shows survival edge over Tecentriq, Opdivo in older patients with lung cancer
3
Two studies underscore need for more effective, bladder-sparing therapies in high-risk cancer
4
Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints
5

















































